ArticleJournal of Alzheimer's disease : JAD2018
Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.
Article in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02414347 (F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A
Who cites it
10 citing papers in PubMed.
- Leveraging Naturalistic Driving Digital Biomarkers for Early Mild Cognitive Impairment Detection: Deep Learning Strategies.JMIR medical informatics · 2026Article
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- Everyday Driving and Plasma Biomarkers in Alzheimer's Disease: Leveraging Artificial Intelligence to Expand Our Diagnostic Toolkit.Journal of Alzheimer's disease : JAD · 2023Article
- Article
- Driving assessment in preclinical Alzheimer's disease: progress to date and the path forward.Alzheimer's research & therapy · 2022Review
- Verbal Learning as a predictor of risks of accidents in elderly drivers.Arquivos de neuro-psiquiatria · 2022Article
- Improving Our Understanding of Driving Changes in Preclinical and Early Symptomatic Alzheimer's Disease: The Role of Naturalistic Driving Studies.Journal of Alzheimer's disease reports · 2022Review
- Using Naturalistic Driving Data to Predict Mild Cognitive Impairment and Dementia: Preliminary Findings from the Longitudinal Research on Aging Drivers (LongROAD) Study.Geriatrics (Basel, Switzerland) · 2021Article
- Using the A/T/N Framework to Examine Driving in Preclinical AD.Geriatrics (Basel, Switzerland) · 2018Article
- Driving Ability in Alzheimer Disease Spectrum: Neural Basis, Assessment, and Potential Use of Optic Flow Event-Related Potentials.Frontiers in neurology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Abnormal levels of Alzheimer's disease (AD) biomarkers, measured by positron emission tomography imaging using amyloid-based radiotracers and cerebrospinal fluid, are associated with impaired driving performance in older adults. We examined whether preclinical AD staging, defined using amyloid imaging and tau imaging using the radiotracer T807 (AKA flortaucipir or AV-1451), was associated with receiving a marginal/fail rating on a standardized road test (n = 42). Participants at Stage 2 (positive amyloid and tau scans) of preclinical AD were more likely to receive a marginal/fail rating compared to participants at Stage 0 or 1. Stage 2 preclinical AD may manifest in worse driving performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.